Lentiviral Particle Production
Lentiviral Particle Production - Related Videos
08:46
Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System
0 Views •
Cited by 44 •
2012
In this protocol we describe production, purification and titration of lentiviral vectors. We provide an example of lentiviral vector-mediated gene delivery in primary cultured neurons and astrocytes. Our methods may also apply to other cell types in vitro and in vivo.
04:12
Production and Purification of Recombinant Hepatitis B Virus Particles
0 Views •
2026
Source: Nishitsuji, H., et al. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J. Vis. Exp. (2017)This video demonstrates the production and purification of recombinant Hepatitis B virus particles, enabling safe, replication-deficient viral preparations for studying early infection events and for high-throughput antiviral drug screening applications.
10:42
A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
0 Views •
Cited by 21 •
2017
We describe the production strategy of integrase-deficient lentiviral vectors (IDLVs) as vehicles for delivering CRISPR/Cas9 to cells. With an ability to mediate quick and robust gene editing in cells, IDLVs present a safer and equally effective vector platform for gene delivery compared to integrase-competent vectors.
03:36
Production of Retroviral Particles for Gene Transfer
0 Views •
2026
Source: Zjablovskaja, P., et al., Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells. J. Vis. Exp. (2018)This video demonstrates the production of recombinant retroviral particles by transfecting human kidney-derived packaging cells, enabling stable gene delivery to target cells for downstream applications such as genetic modification, functional assays, or lineage differentiation studies.
03:41
Production of Virus-like Particles in Engineered E. coli
0 Views •
2026
Source: Chen, Z., et al. Making Conjugation-induced Fluorescent PEGylated Virus-like Particles by Dibromomaleimide-disulfide Chemistry. J. Vis. Exp. (2018)This video demonstrates the method for the controlled expression of the bacteriophage Qβ coat protein in engineered E. coli. The resulting proteins self-assemble into virus-like particles, which are harvested for downstream bioconjugation.
FAQs
Each component group contributes a different function to the production system. The vector component contains the transgene to be delivered, whereas packaging and envelope components support formation of particles capable of entering recipient cells. Keeping these roles conceptually distinct helps researchers interpret production results and connect vector design with downstream delivery and gene-expression outcomes.
Integration into the host genome matters because it can maintain transgene presence beyond the initial delivery event. This provides a basis for stable gene expression in cultured cells and model systems, rather than limiting analysis to an immediate response after exposure. Consequently, lentiviral vectors are useful when experiments require persistent expression to examine gene function or disease mechanisms.
Producer cells generate and release the particles after receiving the vector, packaging, and envelope components. Recipient cells, by contrast, are the biological targets that receive the carried genetic material. Separating these roles helps researchers distinguish particle production from delivery and evaluate whether an outcome reflects vector generation, cell entry, or subsequent transgene expression.
A basic workflow introduces vector, packaging, and envelope components into producer cells. Those cells assemble and release lentiviral particles, which are then used to enter recipient cells and deliver the transgene. This sequence connects production with downstream gene transfer, allowing researchers to relate the quality of particle generation to delivery efficiency and expression in target cells.
Characterization should focus on vector quality, delivery efficiency, and reproducibility across experiments. These outcomes indicate whether the production process consistently generates particles that can deliver the intended transgene to recipient cells and support the expected expression pattern. Monitoring them helps researchers identify variability in the system and improve the reliability of cultured-cell or model-system studies.
This approach is useful when researchers need stable transgene expression in cultured cells or model systems. It supports investigations of gene function and disease mechanisms, and it also provides a vector platform relevant to cell-based therapies. Its value comes from combining genetic delivery with persistence, enabling experiments that require expression to continue after the initial exposure.